NextCure Stock Discussion

$NextCure (NXTC.US)$
NextCure Announces Acceptance of IND Application for LNCB74
Tuesday, 10th December at 8:05 am
BELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) accepted an Investigational New Drug (IND) application for initiation of a Phase 1 c...

$NextCure (NXTC.US)$
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
NextCure announced preclinical data showing that NC605, their anti-Siglec-15 antibody, enhanced quality bone generation with improved mechanical properties in mice with Osteogenesis Imperfecta (OI). The study used NP159, a surrogate antibody to NC605, at 20 mg/kg dosage. Key results showed 90% ...

$NextCure (NXTC.US)$
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
NextCure (NXTC) presented preclinical data for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC), and additional biomarker data for NC410 combination therapy at SITC. LNCB74 showed promising results with strong anti-tumor activity in multiple tumor models and favorable safety profile, with IND filing expected by y...

$NextCure (NXTC.US)$
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
NextCure Inc (Nasdaq: NXTC) announced two presentations at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in Houston, TX from November 6-10, 2024. The company will present:
1. Pre-clinical data on LNCB74, a B7-H4 antibody-drug conjugate, in a poster session on November 8.
2. Biomarker data from the NC410 combination study with pembrolizumab in ICI-naïve MSS/M...

Pre-Market Stock Movers
Gapping up
$Sagimet Biosciences (SGMT.US)$
(Shares of the biopharmaceutical company popped 31% following an upgrade from Goldman Sachs. The firm highlighted Sagimet could see strong gains thanks to progress on a treatment for  non-alcoholic steatohepatitis.）
$Eli Lilly and Co (LLY.US)$
(The pharmaceutical stock climbed 8.6% after an earnings beat. The company reported an adjusted $2.11 per share ...